<DOC>
	<DOCNO>NCT02788006</DOCNO>
	<brief_summary>Multicenter prospective phase II study evaluate regorafenib old patient metastatic colorectal cancer</brief_summary>
	<brief_title>Phase II Study Evaluating Efficacy Safety Regorafenib Patients Aged More Than 70 Years With Metastatic Colorectal Adenocarcinoma .</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>Metastatic colorectal cancer histological proof Measurable disease accord RECIST 1.1 Age ≥ 70 year ECOG ≤ 1 Biological value Haemoglobin ≥ 9 g/dL , PNN ≥ 1500/mm3 , platelets≥ 100 000/mm3 , bilirubin ≤ 1,5N , ASAT , ALAT et PAL ≤ 2,5N ( ≤ 5N hepatic metastasis ) , lipase ≤1,5N , TP≥ 70 % , Creatinine clairance ≥ 30 mL/min Patient without response 5FU chemotherapy antivegf treatment anti EGFR treatment ( RAS wildtype ) , progression treatment treatment stop toxicity Geriatric Questionnaires answered Lifeexpectancy ≥ 3 month Informed Consent Signed Not able swallow tablet ( crush tablet allow ) Previous treatment regorafenib multikinase treatment Other cancer last 5 year , except insitu cervix cancer , skin cancer non melanoma cancer bladder curatively treat Radiotherapy : extend field last 4 week , limit field last 2 week previous inclusion Toxicity &gt; grade 1 resolve previous treatment Major surgery 28 day inclusion Non cicatrize injury , ulcer bone fracture Congestive Cardiac insufficiency classe &gt; 2 ( NYHA ) Unstable angor last 3 month Myocardial Infraction 6 month inclusion HTA control Pheochromocytome Arterial venous thromboembolism past 6 month Infection grade &gt; 2 VIH infection B C hepatitis necessiting specific treatment Cirrhosis Suspicion brain metastasis brain metastasis Haemorraghe ofgrade &gt; 3 last week Symptomatic Pulmonary fibrosis Proteinuria &gt; grade 3 Malabsorption Allergy know treatment one similar treatment one treatment component Systemic anticancer drug study last 4 week Concomitant treatment CYP3A4 inhibitor inductor UGT1A9 inhibitor Social , psychological medical condition interfere study participation</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>